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SPONDYLARTHOPATHIESThe SAPHO Syndrome
Minhchau Thi Nguyen, MD,* Andrea Borchers, PhD,*
Carlo Selmi, MD,*,† Stanley M. Naguwa, MD,* Gurtej Cheema, MD,*
and M. Eric Gershwin, MD*
Objective: To review the epidemiology, presentation, diagnosis, treatment, pathogenesis, and
genetics of the syndrome known under the acronym of SAPHO for Synovitis, Acne, Pustulosis,
Hyperostosis, and Osteitis to heighten awareness of this entity.
Methods: We conducted a Medline search using SAPHO syndrome, chronic recurrent multifocal
osteitis/osteomyelitis, and related terms as keywords and extracted further relevant articles from
the retrieved references.
Results: The SAHPO acronym identifies a syndrome encompassing a variety of osteoarticular
disorders that are frequently accompanied by dermatoses characterized by neutrophilic pseudoab-
scesses, but can also occur in isolation. SAPHO syndrome is rare, although probably underrecog-
nized because its diagnosis may be challenging because of the wide variability in its musculoskeletal
and cutaneous manifestations. This is especially true when atypical sites are involved and when
specific skin lesions are absent. There are no standardized treatment protocols available. Current
treatments are empirical and have the objective of providing relief from the at times debilitating
pain associated with SAPHO syndrome. They include nonsteroidal anti-inflammatory drugs and
analgesics as first-line agents. Systemic corticosteroids, disease-modifying anti-rheumatic drugs,
biologicals targeting tumor necrosis factor alpha and interleukin-1, and bisphosphonates have all
been beneficial in some patients, but ineffective in others. This suggests that the pathogenesis of
SAPHO syndrome is multifactorial, but this aspect remains poorly explored, although bacteria
and immunological dysfunction are hypothesized to play a role.
Conclusions: The early recognition, diagnosis, and prompt treatment of SAPHO syndrome can
prevent the unnecessary use of long-term antibiotics or invasive procedures, while rapidly allevi-
ating pain in a majority of affected patients.
© 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 42:254-265
Keywords: synovitis, acne, pustulosis, hyperostosis, osteitis
d
b
h
q
t
p
c
c
b
p
h
d
a
i
tStarting in the 1960s, there have been reports of anassociation between cutaneous manifestations, inparticular palmoplantar pustulosis (PPP), pustular
soriasis, hidradenitis suppurativa, and severe acne (ful-
inans or conglobata), with certain osteoarticular mani-
estations like peripheral synovitis or aseptic osteitis af-
ecting the anterior chest wall and other skeletal sites.
ince then, more than 50 designations have been used to
*Division of Rheumatology, Allergy and Clinical Immunology, University of Cali-
fornia, Davis.
†Clinical Immunology, IRCCS Istituto Clinico Humanitas, Milan, Italy.
Address reprint requests to M. Eric Gershwin, MD, Division of Rheumatology, Allergy
and Clinical Immunology, University of California, Davis School of Medicine, 451u
Health Sciences Drive, Suite 6510, Davis, CA 95616. E-mail: megershwin@
cdavis.edu.
254 0049-0172/12/$-see front matter © 2012 Elsevier Inc. All rights reserved
http://dx.doi.org/10.1016/j.semarthrit.2012.05.006escribe these combinations, the more common ones
eing pustulotic arthro-osteitis, sternocostoclavicular
yperostosis, acne-associated spondyloarthropathy, ac-
uired hyperostosis syndrome, or chronic recurrent mul-
ifocal osteomyelitis. A group of French researchers, sus-
ecting that these disorders might share common
haracteristics, conducted a national investigation of such
ases (1). Their results indicated that a specific type of
one involvement, namely inflammatory osteitis with hy-
erostosis, constituted a common denominator and ex-
ibited the same characteristics whether accompanied by
ermatologic manifestations or not. These bone lesions
re mainly localized in the anterior chest wall, but may
nvolve any skeletal segment (2). As a unifying concept,
he French researchers proposed to group these disorders
nder the acronym SAPHO (originally Syndrome Acne
.
M.T. Nguyen et al. 255Pustulosis Hyperostosis Osteitis, the “S” being changed to
Synovitis the following year) (1,3). Even though pustular
dermatoses originally appeared to be the unifying ele-
ment, their presence is not absolutely required because (1)
the typical osteoarticular manifestations are identical in
the absence or presence of cutaneous involvement and (2)
it has since become more fully appreciated that dermato-
logic manifestations can occur years before bone lesions
and may have been forgotten, but can also develop long
after the osteoarticular lesions.
Note that the original description of the SAPHO syn-
drome and the inclusion criteria proposed for this entity
specifically include cases of chronic recurrent multifocal
osteomyelitis (CRMO) (1,3). This condition was first de-
scribed by Giedion et al. in 1972 (4) under the name of
subacute and chronic symmetrical osteomyelitis, and
most frequently affects children, but has been reported in
adults (5-8), whereas typical manifestations of SAPHO
syndrome have been described in children (9). There still
is some debate over whether CRMO represents the pedi-
atric form of SAPHO or constitutes a separate entity.
However, CRMO exhibits all the essential features of the
SAPHO syndrome, including osteitis; hyperostosis; and
the association with skin disorders such as PPP, severe
acne, pyoderma gangrenosum, and, in rare cases, Sweet
syndrome—although in a lower proportion of cases
(30% compared to 50% to 85% in adults). In addition,
CRMO-like SAPHO syndrome is associated with inflam-
matory bowel disease (IBD) (10-13). However, CRMO
most frequently affects the metaphyses of tubular bones,
whereas other forms of SAPHO syndrome most often
involve the axial skeleton, particularly the anterior chest
wall. CRMO can affect the sternocostoclavicular region,
but this generally manifests as hyperostosis of the medial
end of the clavicle and, unlike in adults, spares other ele-
ments of this region, including the sternoclavicular joint
(14). Nonetheless, in the following, CRMO is considered
a subtype of the SAPHO syndrome that affects children
much more frequently than adults.
SAPHO syndrome is generally considered to be a rare
condition, possibly due to being underdiagnosed. A prev-
alence estimate of 1/10,000 is frequently mentioned,
although it is unclear what this is derived from because
there are no actual data. Based on long years of experience
with SAPHO, a German rheumatologist and SAPHO
expert estimates its prevalence to lie somewhere between
that of systemic lupus erythematosus and scleroderma and
provides a figure of 0.04% (ie, 40/100,000) (15). In the
original collection of French SAPHO cases overall, the
gender distribution was approximately equal (1). Since
then, the majority of cohorts comprising more than 20
patients were characterized by a female preponderance,
including various patient groups from France, Italy, and
Japan (16-20), as had already been noted in an earlier
description of pustulotic arthro-osteitis (21). An excep-
tion is a Spanish cohort, for which equal numbers of men
and women were reported (22). The SAPHO syndromemay present at any age but is most commonly seen in
children and young to middle-aged adults (16,17).
CLINICAL PRESENTATION
The osteoarticular involvement is generally insidious in
onset, but eventually patients will present with pain that is
frequently dramatic and incapacitating and may be exac-
erbated by movement or application of pressure. Soft tis-
sue swelling, often with redness and heat, and limitation
of motion at the affected skeletal site(s) are other present-
ing signs. Morning stiffness is quite frequently reported
ranging in severity from mild to lasting several hours, and
in cases of long bone involvement, a limp may be evident.
Of note, quite a few cases of CRMO were preceded by
trauma (23-26). Systemic manifestations are uncommon;
however, fever is sometimes reported and modest eleva-
tions of erythrocyte sedimentation rate or C reactive pro-
tein are common.
In adults, the most commonly affected skeletal site is
the anterior chest wall (65% to 90%, Table 1), followed
by the spine (in 30%), with the thoracic spine being
most frequently affected, followed by the lumbar and
then the cervical spine (2,27). Sacroiliitis is seen in up to
13% to 52% of patients with SAPHO syndrome (2,27).
The appendicular skeleton is not a frequent localization in
adults with SAPHO syndrome, with 5% to 10% of them
showing involvement of the long bones, and 1% to 10%
of patients experiencing mandibular lesions. In contrast,
long bones represent the most frequent site of involve-
ment in children, where the distal and proximal tibia are
most commonly affected, followed by the proximal and
distal femur (10,14,23,28). Lesions of spine, clavicle, pel-
vis, and other sites are reported with highly variable fre-
quencies. In both adults and children, there can be arthri-
tis of the articulations adjacent to bone lesions, ie, the
anterior chest wall and sacroiliac joints in adults, the an-
kles and knees in children (10,23,28). Synovitis in periph-
eral joints distant from the sites of bone involvement is
seen in30% of adults, but more rarely in children (10).
Skin manifestations may be evident at the time of pre-
sentation with osteoarticular symptoms, but may have
occurred years earlier or may develop later. In an early
description of 53 cases, skin involvement occurred within
an interval of 2 years before or after the onset of rheuma-
tological symptoms in 70% of cases (21), but delays of up
to nearly 4 decades have been reported (16,21,29). In the
largest cohorts described to date, skin involvement pre-
ceded musculoskeletal symptoms in 40% to 68% of pa-
tients, occurred simultaneously in30% of patients, and
manifested later in 32% to 60% of cases (16,17,22). At
least 15% of adults and more than 70% of children may
never experience skin lesions, whereas others may exhibit
2 or even 3 different ones. The cutaneous lesions are neu-
trophilic dermatoses. The most common one is PPP, rep-
resenting 50% to 75% of all dermatologic manifestations
(Table 1) and affecting close to 60% of patients with
psoria
256 The SAPHO syndromeextended follow-up (16,17). Of note, many pathologists
feel that PPP cannot be distinguished unequivocally from
pustular psoriasis, and it has become customary to sub-
sume both entities under pustulosis or PPP. There is still
some debate over whether psoriasis vulgaris should be
included among the dermatologic manifestations of
SAPHO. Although it may represent up to one third of all
skin involvement, it is frequently seen in combination
with PPP or severe acne and occurs in isolation in only 5%
to 10% of cases. Severe acne, ie, acne conglobata and
fulminans, affects approximately one fourth of patients
with SAPHO syndrome, with men clearly predominating
(1,16). Hidranetitis suppurativa (also called acne inversa)
is considered to be a severe form of acne by some and to
represent a distinct entity that resembles acne by others. It
mainly affects women, yet men predominate among the
cases of SAPHO syndrome that have been reported in
association with hidradenitis suppurativa (30-32). Afri-
Table 1 Frequency of Clinical Manifestations in SAPHO Pat
Reference (1
Country France
n 12
Age at diagnosis (mean, range) 37.7 (
Male/female 50
Years of study 1974
Follow-up (yr) Mean 4.
1-23)
Anterior chest wall involvement (%) 6
Inflammatory back pain (%) N
Spinal (%) 3
Sacroiliitis (%) 4
Long bones/peripheral (%)
Mandible (%) 1
Peripheral arthritis (%) 3
Cutaneous manifestations (N/%) 110 (
Of those (in %)
PPP overall 58
Severe acne overall 2
Psoriasis vulgaris overall
PPP, isolated 3
PPP  psoriasis vulgaris 2
PPP  severe acne
PPP  hidradenitis suppurativa
Psoriasis vulgaris, isolated 1
Severe acne, isolated 2
Severe acne  hidradenitis
suppurativa
Other manifestations
Inflammatory bowel disease (n/%) 9
Of those Crohn’s disease 6/9
Of those ulcerative colitis 3/9
HLA-B27 (%) 1
NA, not available; PPP, palmoplantar pustulosis.
aMedian and interquartile range.
bCannot be determined exactly from the data provided because so
and/or PV were reported.
cThis figure is for the combination of severe acne with PPP and/orcan Americans appear to be particularly susceptible.Other rare cutaneous manifestations of the SAPHO syn-
drome include pyoderma gangrenosum and Sweet’s syn-
drome (17,33-35). Skin involvement is not as frequent in
children compared to adults.
RADIOLOGY
Radiography
Two of the osteoarticular manifestations of SAPHO syn-
drome are hyperostosis and osteitis, which are chronic
inflammatory reactions involving the cortical and medul-
lary bone. In the initial stages of the disease, radiographs
of affected areas are often normal. Early lesions are often
purely osteolytic with or without a sclerotic margin, typ-
ically accompanied by an endosteal or periosteal reaction
(14). With disease progression, these lesions become
mixed lytic/sclerotic or entirely sclerotic (14). Chronic
(24) (19)
France Italy
52 71
42 (15-73) 45.5 (35.7-54.0)a
26/26 23/48
1984-2007 1990-2008
ge NA 0
73 70
13 24
34
27
33
63 40 (56)
52 65
39 25
33 7.5
50
0
12
2
8
23
5
2 (4) 2 (3)
2/2 (100%) 2/2 (100%)
0 0
18 4
tients with SA had both PPP and PV, and only data for SA plus PPP
sis vulgaris.ients
8)
0
5-67)
/70
-1997
9 (ran
3
A
3
0
5.8
0.8
3
84)
b
9.7
c
7.6
0.8
7.9c
1.9
1.8
(7.5)
(67%)
(33%)
3
me palesions are predominantly sclerotic, with cortical thicken-
M.T. Nguyen et al. 257ing accompanied by narrowing of the medullary canal and
enlargement of trabeculae.
Anterior Chest Wall
Anterior chest wall lesions can involve any component of
the sternocostoclavicular region. Lesions usually develop
in 3 stages: stage 1 is localized to the area of the costocla-
vicular ligament and may manifest as a primary en-
thesopathy; in stage 2, an arthropathy of the sternoclavic-
ular joint develops with osteolytic and osteosclerotic
changes of the medial end of the clavicle and adjacent
structure, such as sternum, first rib, and costal cartilage;
and stage 3 marks the progression of osteosclerosis, hyper-
ostosis, and hypertrophy of these and other surrounding
structures (2,27). Adjacent joints may develop arthritis or
ankylosis. In contrast to adults, only the clavicle is in-
volved in children, whereas the sternoclavicular joint,
sternum, and ribs are rarely affected. Ossification of the
costoclavicular ligament and first costal cartilage with
bony masses extending to the region between clavicle and
first rib and ankylosis of the sternoclavicular joint has
been described in adults, particularly in Japanese patients
(36,37), but not in children.
Axial Skeleton
Spinal involvement is usually segmental, most commonly
affecting a single vertebra, although occasionally up to 4
adjacent vertebrae, but an individual patient may have up
to 5 such lesions (2,27,38). Manifestations in the axial
skeleton can take a variety of forms and can occur in
various combinations. They include osteosclerosis of one
or more vertebral bodies with development of hyperosto-
sis; osteolytic lesions with variable degree of vertebral col-
lapse; spondylitis with or without discitis, in the latter case
resembling infectious spondylodiscitis; paravertebral ossi-
fications; and sacroiliitis (2,27). Paravertebral ossifica-
tions in SAPHO syndrome most commonly are nonmar-
ginal and asymmetrical syndesmophytes similar to, but
not identical with, the syndesmophytes seen in psoriasis
(2,27). Note, however, that others consider them to be
enthesophytes rather than true syndesmophytes (17). In
chronic cases, florid hyperostosis may result in massive
bony bridging, which can evolve into ankylosis of the
adjacent disk spaces and associated kyphosis. Once anky-
losis is complete, hyperostosis has been observed to re-
solve (17). The sacroiliitis of SAPHO syndrome is more
frequently unilateral than seen in ankylosing spondylitis
and is characterized by sclerosis and hyperostosis primar-
ily on the iliac side of the joint.
Appendicular Skeleton
The long bones are infrequently involved in adult pa-
tients, but represent the most common site of involve-
ment in children. In the early stages, they typically show
osteolysis in the metaphysis adjacent to the growth plate(2,14). The extent of periosteal reaction depends on the
size of the involved bone, generally being more pro-
nounced in small-diameter bones (14). The lesions heal
with sclerosis and progressive hyperostosis. The disorder
originally called diffuse sclerosing osteomyelitis of the
mandible is now recognized to represent a form of
SAPHO syndrome, whether occurring in isolation or in
conjunction with bone lesions at other sites. It is seen in
up to 10% of patients, usually affects the corpus and
ramus, while the temporomandibular joint is often
spared, and is frequently accompanied by painful swelling
of the overlying soft tissue (2,27,39). Mandibular lesions
are characterized by diffuse unilateral sclerosis, often as-
sociated with pronounced periosteal reaction.
Other Imaging Modalities
Whole-body scintigraphy is useful because it not only
shows increased tracer uptake in the affected bone but
frequently reveals clinically silent lesions. High tracer up-
take in the sternocostoclavicular region yields the so-
called “bull’s head sign,” with the manubrium sterni
representing the upper skull and the inflamed sternocla-
vicular joint with the adjacent claviculae forming the
horns (40). This configuration is virtually pathognomonic
for SAPHO syndrome, but is not entirely sensitive, although
it may even be present in SAPHO patients who do not report
symptoms of the anterior chest wall (41).
Whole-body magnetic resonance imaging (MRI) has
the same sensitivity as whole-body scintigraphy, but the
added advantage of avoiding radiation exposure, which
becomes particularly important when repeated imaging is
necessary during follow-up. Conventional MRI is not
only considerably more sensitive than radiography, but
also can show marrow edema as well as adjacent soft tissue
inflammation. It is particularly helpful in examining ver-
tebral bodies and can be used to monitor disease progres-
sion because chronic sclerotic bone lesions exhibit low
signal intensity in both T1- and T2-weighted images,
whereas active lesions appear hypointense on T1- and
hyperintense on T2-weighted images. Computed tomog-
raphy, especially multi-slice computed tomography with
secondary reconstructions, is best suited for a detailed
depiction of the osteoarticular lesions and is the imaging
modality of choice for the sternoclavicular region, which
is difficult to visualize by conventional radiographs due to
the superimposition of ribs, spine, and mediastinum.
HISTOLOGY
The histologic characteristics of the bone lesions change
over the course of the disease. In the early stages, there is
acute inflammation with a predominantly neutrophilic
infiltrate, and both bone resorption and prominent peri-
osteal bone formation have been described (5,42,43). In
biopsy specimens from children with CRMO, multinu-
cleated giant cells, granulomatous foci, and necrotic bone
fragments have been observed (5,44). Subsequently, the
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258 The SAPHO syndromeinfiltrate consists of scattered lymphocytes, plasma cells,
histiocytes, and only a few polymorphonuclear cells
(5,42,43). Memory T lymphocytes of the CD8 subset
onstitute the major cell type (45). In the late stages, the
nfiltrate is sparse or absent and enlarged sclerotic trabec-
lae as well as marrow fibrosis are observed. There are
Table 2 Inclusion and Exclusion Features of the SAPHO
Syndrome (3)
Inclusion features Osteo-articular manifestations of
acne conglobata, acne
fulminans, or hidradenitis
suppurativa
Osteo-articular manifestations of
PPP
Hyperostosis (of the anterior
chest wall, limbs or spine)
with or without dermatosis
CRMO involving the axial or
peripheral skeleton with or
without dermatosis
Sometimes reported Possible association with
psoriasis vulgaris
Possible association with an
inflammatory enterocolopathy
Features of ankylosing
spondylitis
Presence of low-virulence
bacterial infections
Exclusion features Septic osteomyelitis
Infectious chest wall arthritis
Infections PPP
Palmo-plantar keratodermia
DISH except for fortuitous
association
Osteoarticular manifestations of
retinoid therapy
The presence of 1 of the 4 inclusion features is sufficient for a
patient to be included in the SAPHO syndrome.
Table 3 Proposed Major and Minor Diagnostic Criteria of N
Major Diagnostic Criteria
(1) Radiologically proven osteolytic/-sclerotic bone lesion
(2) Multifocal bone lesions
(3) PPP or psoriasis
(4) Sterile bone biopsy with signs of inflammation and/
or fibrosis, sclerosis
Two major or 1 major and 3 minor criteria must be fulfilled for a
As a reminder, CRMO is a subtype of NBO, requiring either mult
a chronic (6 mo) relapsing-remitting disease course (8). Multifoc
addition, the proposed diagnostic criteria of NBO include only PP
other dermatologic manifestations have been described in children
syndrome include severe acne and hidradenitis suppurativa in add
debate, with the criteria proposed by Benhamou et al. (3) listing t
autoimmune disease in the patients themselves or in first- or secon
those for SAPHO syndrome.increased numbers of osteoblasts and occasionally oste-
oclasts as well (5,42,43).
DIAGNOSIS
Because the signs and symptoms of SAPHO syndrome are
nonspecific and the osteoarticular manifestations cover a
broad spectrum, the diagnosis is one of exclusion. There
are no validated diagnostic criteria, but many physicians
apply the inclusion and exclusion criteria formulated by
Benhamou et al. (3) (Table 2). The presence of only 1 of
the 4 inclusion criteria is sufficient to arrive at a diagnosis
of SAPHO syndrome. Separate diagnostic criteria have
been proposed for nonbacterial osteitis, which includes
CRMO (Table 3) (11). The diagnosis is relatively
straightforward in patients with typical localizations of
pain (eg, the anterior chest wall), the corresponding ra-
diographic findings, and characteristic skin lesions. It is
much more challenging when atypical sites are involved
or skin manifestations are absent, and it becomes impos-
sible in patients with single skeletal lesions that lack signs
of hyperostosis. A detailed history, inquiring specifically
about previous cutaneous and skeletal involvement, may
provide diagnostic clues. Whole-body scintigraphy or
MRI may reveal additional clinically silent sites of osteo-
articular involvement. The bone lesions of SAPHO may
not be distinguishable from infectious osteomyelitis or
bone neoplasms, which must be excluded through a bi-
opsy yielding the appropriate histologic findings and neg-
ative bacterial cultures. The main differential diagnoses of
SAPHO syndrome include infectious osteomyelitis, os-
teosarcoma, Ewing sarcoma, bony metastasis, eosino-
philic granuloma, Paget’s disease, infectious spondylodis-
citis, sternoclavicular osteoarthritis, condensing osteitis of
the clavicle, and osteonecrosis of the medial clavicular
epiphysis (13,46). In children, juvenile idiopathic arthri-
tis constitutes another differential diagnosis. For example,
in a French CRMO cohort, initial diagnoses were infec-
8)
Minor Diagnostic Criteria
A) Normal blood count and good general state of health
B) CRP and ESR mildly to moderately elevated
C) Observation time longer than 6 mo
D) Hyperostosis
E) Associated with other autoimmune diseases apart
from PPP or psoriasis
F) Grade I or II relatives with autoimmune or
autoinflammatory disease, or with NBO
sis of NBO.
one lesions or a single lesion associated with PPP or psoriasis and
d chronicity are not required for inclusion in SAPHO syndrome. In
soriasis, even though severe acne, pyoderma gangrenosum, and
RMO (5,6). In contrast, the proposed inclusion criteria for SAPHO
o PPP. The status of psoriasis vulgaris in SAPHO is still a matter of
dition only as “sometimes reported.” An association with another
ee relatives features only in the proposed criteria for NBO, but notBO (
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M.T. Nguyen et al. 259tious osteomyelitis in 6 of 14 patients, bone tumor in 2,
and juvenile idiopathic arthritis in 2 (47). Chest pain due
to anterior chest wall involvement may be mistaken for an
acute cardiac event (17).
TREATMENT
Nonsteroidal Anti-Inflammatory
Drugs (NSAIDs) and Analgesics
Due to the rarity of the SAPHO syndrome, no random-
ized controlled clinical trials have been conducted to eval-
uate the efficacy of individual therapeutic modalities.
Consequently, treatment is not evidence-based, but de-
rived from observations in published case reports and
small case series, along with expert judgment. Therapy is
aimed at symptom relief and mainly includes NSAIDs
and analgesics as first-line agents. However, at least one
half of all SAPHO patients do not experience sufficient
pain relief and protection from disease exacerbations with
such conservative therapy (1,17). Because of the similarity
between the osteitis of SAPHO syndrome and particu-
larly of CRMO with infectious osteomyelitis, numerous
patients have been treated with antimicrobial agents, even
if bacterial cultures prepared from their biopsy yielded
negative results. The vast majority of patients did not
derive any benefit from such therapy. However, there
have been a few reports of positive responses (eg, in 4/20
patients in a large French cohort (16), and 2/9 patients in
a group of Italian patients) (17). Propionibacterium acne is
low-virulence pathogen suspected of playing a role in
APHO syndrome (48). In 14 German patients whose
iopsy was positive for P. acne and another 13 patients
who had not undergone a biopsy, a 16-week course of
antimicrobial therapy was associated with a significant
decrease in disease activity of both the osteitis and the
dermatologic lesions (49). However, disease activity re-
turned to baseline levels within 3 months following dis-
continuation of therapy.
Corticosteroids and Disease-Modifying
Anti-Rheumatic Drugs (DMARDs)
In patients refractory to NSAIDs and analgesics, cortico-
steroids can be quite effective, particularly when given as
intra-articular injections (1,16,25,50). However, some
patients experience only partial or no relief or require
doses high enough to induce Cushing syndrome (51-53)
and relapse after treatment withdrawal has been observed
(47). As steroid-sparing agents or in refractory cases, the
use of DMARDs, particularly methotrexate, sulfasalazine,
or azathioprine, has been reported to be beneficial in some
patients, although ineffective in others (11,16,54).
Biologicals
Treatment with biologicals that antagonize tumor necro-
sis factor (TNF) has shown promising results in cases of
SAPHO syndrome refractory to NSAIDs, corticoste- eroids, and DMARDs, including several children (54-61).
The most frequently used TNF antagonist is infliximab,
but a few patients treated with etanercept or adalimumab
have also been described. The most common dosage
schedules are summarized in Table 4, but higher doses—
achieved either by increasing the individual dose or by
shortening the dosage intervals—have been found neces-
sary in some patients. The response is generally rapid,
with dramatic improvement even after the first dose, but
more gradual improvement can also occur. Remission of
bone pain has been reported in the majority of patients,
but generally requires continued therapy. However, there
are also reports of patients who did not benefit from
TNF blockade (62). Follow-up has been short in most
ases reported to date. Only a limited number of patients
nderwent repeat imaging studies. In some of these, there
as evidence of continued subclinical disease activity with
ersistence of existing lesions or even development of
ew, clinically silent lesions, even though pain had sub-
ided completely under TNF blockade (59). The skin
esions initially improve, and complete remission of acne
nd PPP has been described in some patients, but recur-
ence, particularly of PPP, was observed in several cases
54,63). As has been noted in other indications of TNF
lockade, individual patients show differential clinical re-
ponses and adverse event profiles to the 3 types of TNF
ntagonists; therefore, switching of a patient to different
ntagonists can be beneficial. Even though there are indi-
ations that TNF antagonists are somewhat less effective
han in other rheumatic diseases, their use should be con-
idered in patients whose SAPHO syndrome is refractory
o other therapeutic regimens.
Of note, it has been reported that SAPHO syndrome
with PPP and spondylitis) developed during infliximab
herapy of a patient with Crohn’s disease (64). Up to 10%
f SAPHO patients develop IBD, most frequently
rohn’s disease and mainly after the onset of SAPHO
ymptoms (8,10-12,16,17,22). Nonetheless, the develop-
ent of SAPHO syndrome during infliximab treatment
s unexpected in view of the successful treatment of this
yndrome with infliximab. Note, however, that the para-
oxical induction of diseases that are often successfully
reated with TNF blockade is a well-known phenomenon
65). In particular, the development of psoriasis has been
bserved in patients with various rheumatic diseases un-
ergoing treatment with biologicals and has also been
eported in patients with SAPHO syndrome (54). How-
ver, this is the first—and so far only—case of SAPHO
yndrome arising during treatment with infliximab (64).
isphosphonates
isphosphonates inhibit bone resorption and have some
nti-inflammatory properties. Several small case series
nd case reports indicate that open-label use of intrave-
ous bisphosphonates results in marked pain relief and
ven sustained remission in a considerable portion of
ab
le
4
G
en
e
M
ut
at
io
ns
Le
ad
in
g
to
H
um
an
G
en
et
ic
A
ut
o-
In
fla
m
m
at
or
y
D
is
or
de
rs
w
ith
Fe
at
ur
es
of
SA
PH
O
an
d
th
e
Re
su
lts
of
G
en
et
ic
A
na
ly
se
s
in
SA
PH
O
/C
RM
O
at
ie
nt
s G
en
e
En
co
de
d
Pr
ot
ei
n
D
is
ea
se
D
is
ea
se
M
an
ife
st
at
io
ns
N
um
be
r
of
SA
PH
O
/C
RM
O
Pa
tie
nt
s
Ex
am
in
ed
Re
su
lts
Re
fe
re
nc
es
PI
N
2
Li
p
in
2
M
aj
ee
d
sy
nd
ro
m
e
A
ne
m
ia
du
e
to
co
ng
en
ita
l
er
yt
hr
op
oi
es
is
ab
no
rm
al
iti
es
;
tr
an
si
en
t
ne
ut
ro
p
hi
lic
de
rm
at
os
is
38
SA
PH
O
N
ot
as
so
ci
at
ed
(2
1)
ST
PI
P1
(C
D
2B
P1
)
Pr
ol
in
e
se
rin
e
th
re
on
in
e
p
ho
sp
ha
ta
se
in
te
ra
ct
in
g
p
ro
te
in
1
Pa
p
a
Py
og
en
ic
A
rt
hr
iti
s,
Py
od
er
m
a
ga
ng
re
no
su
m
,
A
cn
e
10
C
RM
O
N
o
m
ut
at
io
ns
(8
)
ST
PI
P2
Pr
ol
in
e
se
rin
e
th
re
on
in
e
p
ho
sp
ha
ta
se
in
te
ra
ct
in
g
p
ro
te
in
2
Tw
o
m
ou
se
m
od
el
s
w
ith
no
ns
yn
on
ym
ou
s
ho
m
oz
yg
ou
s
m
ut
at
io
ns
Fe
at
ur
es
of
C
RM
O
10
C
RM
O
N
o
m
ut
at
io
ns
(8
)
38
SA
PH
O
N
ot
as
so
ci
at
ed
(2
1)
1R
N
IL
-1
RA
D
efi
ci
en
cy
of
th
e
IL
-1
RA
(D
IR
A
)
A
se
p
tic
m
ul
tif
oc
al
os
te
om
ye
lit
is
,
p
er
io
st
iti
s,
p
us
tu
lo
si
s
N
ot
do
ne
N
ot
do
ne
260 The SAPHO syndromepatients refractory to NSAIDs, corticosteroids, and
DMARDS (51,62,66-68), including 2 small series of chil-
dren (69,70). Many other patients experience at least par-
tial improvement, but a number of treatment failures have
also been reported (54,62,67). Pamidronate has been the
most frequently used bisphosphonate, but there are case
reports of good results with other types of bisphospho-
nates (71-74). The dosage schedules for pamidronate
have been highly variable, ranging from a single infusion
of 30 mg (43) to infusions on days 1, 7, 14, 28, and 56
(68), but single infusions of 60 mg repeated as needed or
60 mg on 3 consecutive days with or without re-treatment
are most common (Table 4). The response can be very
rapid, but in most patients several courses of bisphospho-
nates are required to achieve a lasting response. Markers of
bone remodeling, in particular increased levels of serum
cross laps at the beginning of therapy and a marked de-
crease during therapy, may be prognostic of a good
clinical response to pamidronate (67). Interestingly, flares
of cutaneous involvement have also been reported to di-
minish or even subside after bisphosphonate therapy (62),
but this is not a consistent finding (66). Adverse effects of
intravenous bisphosphonates in patients with SAPHO
syndrome consist mostly of fever and flue-like symptoms
particularly during or after the first infusion, but have
included renal dysfunction in other patient groups.
Therefore, it is of particular interest that the use of an
oral bisphosphonate also demonstrated effectiveness in
a patient with SAPHO syndrome (75). Note that re-
peated bone scans do not necessarily show decreased
technetium uptake (62,68), although such cases have
been reported (76).
Surgery
Numerous patients with SAPHO syndrome have under-
gone surgical procedures such as saucerization, decortica-
tion, and partial or complete resection of the affected
bone. Although this was reported to be beneficial in
isolated cases (36,48,77,78), it is generally not recom-
mended because there is a high recurrence rate
(36,48,50,78). Resections may be necessary, however,
in cases of severe functional limitations and important
esthetic concerns, as can occur when the mandible is
affected (39).
DISEASE COURSE AND PROGNOSIS
The course of the disease in individual patients is highly
variable. In a recently described cohort, 13% of patients
had monophasic disease and 35% experienced a relaps-
ing-remitting course for up to a few years, but eventually
reached remission. The disease took a chronic course with
exacerbations separated by brief periods of improvement
in the remaining 52% of patients (17). Predictors of a
chronic disease course in this study were female gender
and the presence at disease onset of anterior chest wall
involvement, peripheral arthritis, dermatologic lesions,T P
L P P IL
M.T. Nguyen et al. 261and high levels of acute phase reactants. In partial con-
trast, 71% of patients in a French cohort experienced
self-limited disease, whereas the disease became chronic in
the remainder (22). Involvement of additional sites dur-
ing the course of the disease is a frequent observation
(16,17,79).
Note that the intervals between flares are highly vari-
able, even in individual patients, and can range from a few
weeks to several months, sometimes even years. In some
cases, exacerbations of bone and skin lesions occur almost
synchronously (24,25), whereas no temporal correlation
between rheumatologic and dermatologic symptoms is
seen in others (16,17). The prognosis is generally consid-
ered to be relatively good. Disabling complications are
rare (16,17), and even patients with chronic disease were
found to experience gradual improvement (79). None-
theless, the peripheral arthritis in SAPHO syndrome may
become erosive in a minority of patients (16,17). When
the inflammation spreads from the affected bones and
joints into the adjacent tissue, soft tissue swelling can
result in venous obstruction and thrombosis. Most fre-
quently, this manifests as thoracic outlet syndrome, sub-
clavian vein obstruction, and superior vena cava syn-
drome (16,27,77). Such soft tissue lesions may be
mistaken for a mediastinal tumor and result in unneces-
sary biopsy or even mutilating surgical procedures unless
there is awareness that this can represent a manifestation
of SAPHO syndrome (77). In addition, approximately
8% to 10% of patients have or develop inflammatory
bowel disease, with Crohn’s disease being 3 to 4 times
more frequent than ulcerative colitis (Table 1) (8,10-
12,16,17,22).
The disease course in children is similarly characterized
by periods of exacerbations and remissions with an in-
creasing number of lesions over time (10), but CRMO is
generally considered to be a relatively benign and self-
limiting disease without major sequelae. Indeed, healing
of lesions with sclerosis and normalization of the bone
structure over a period of 0.5 to 5 years after remission
have been described in children with CRMO (24). None-
theless, the disease remained active in60% of patients 3
to 5 years after diagnosis (28,47). Even a median of 13
years after diagnosis, one fourth of CRMO patients were
found to experience chronic pain due to active disease
(10). Others reported a high frequency of pathologic frac-
tures (49%) and vertebral fractures derived from patho-
logic fractures (44%) in patients with CRMO (11). In
addition, CRMO patients may suffer from permanent
bone deformities and limb length abnormalities and even
generalized growth failure (28,80). Educational outcomes
and career choices may also be affected by CRMO (28).
PATHOGENESIS
The pathogenesis of SAPHO syndrome remains un-
known and the mechanisms linking osteoarticular and
skin lesions are enigmatic. The highly variable response toeach and every treatment modality used to date suggests
that a multitude of pathways is involved. Several hypoth-
eses have been proposed. One is that bone and skin lesions
arise in response to persistent infection with low-virulence
pathogens. Among the microorganisms cultured from
bone biopsies of some patients with SAPHO syndrome,
P. acne has been most frequently identified (48,49,81).
Note, however, that in a vast majority of patients, cultures
are negative, even when tested with polymerase chain re-
action employing universal primers for eubacterial and
mycobacterial genes (45,47), and antibiotics are generally
ineffective, even if a few cases with a good clinical re-
sponse to antimicrobial agents have been described
(16,17). It has also been hypothesized that SAPHO syn-
drome represents an autoimmune process triggered by a
bacterial or viral pathogen via molecular mimicry. None
of these hypotheses explain why skin lesions precede bone
lesion in some patients and follow them in others or why
years or decades can pass between cutaneous and osteoar-
ticular manifestations.
There have been several systematic investigations of
autoantibodies in patients with the SAPHO syndrome
(17,18,82). The results were always negative for rheuma-
toid factor, anti-citrullinated peptide, and extractable nu-
clear antigens with 1 exception (18). Antinuclear antibod-
ies (ANA) were negative in all patients of 1 cohort (82)
and were not detected at presentation, but developed in 2
of 71 patients during follow-up (17). In the third inves-
tigation, however, ANA at titers of 1/160 were detected in
14 of 90 (16%) patients, yet 10 of these patients never
took medications associated with the induction of ANA
(18). ANA at titers 1/80 were found in almost 37% of
this cohort. Similarly, 33% of patients with nonbacterial
osteitis including CRMO were reported to have ANA
titers 1:120 (11). Their specificity could not be deter-
mined. Antithyroid globulin and antithyroid peroxidases
were detected in 2% to 3% of patients in 2 studies
(18,82), but these antibodies were present in 23% and
21% of the patients in another cohort, and 6 patients had
overt hyperthyroidism (17).
Genetics
Considering that there are far less than 1000 published
cases of SAPHO syndrome, the number of familial cases
that have been described is quite substantial. These
concern monozygotic twins (83-85), sibling pairs
(19,50,86,87) and trios (19,88,89), a mother–daughter
pair (90), and several other cases in which the relationship
is not specified (17). In several instances, the affected sib-
lings shared numerous human leukocyte antigens (HLA)
phenotypes (87,88,91). In addition, a family has been
described in which the patient and her grandmother had
SAPHO, the mother had recurrent pustulosis, severe
acne, and intermittent multifocal bone pain that had not
been evaluated, and several other family members had
severe acne and various other skin diseases (92). Of note,
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262 The SAPHO syndromeneutrophils from both the primary patient and her
mother exhibited a defect in the internal oxidative burst of
neutrophils in response to a variety of stimuli (92). This is
noteworthy because neutrophilic pseudoabscesses are
characteristic of the dermatoses associated with SAPHO
syndrome, and the early infiltrate in bone lesions is also
dominated by neutrophils.
Among 89 cases of nonbacterial osteitis, including
CRMO, 6% of the families contained more than 1 af-
fected member, including father and son, father and 2 of
his daughters, monozygotic twin sisters, and 2 other pairs
of sisters (11). In addition, almost 40% of the patients had
a family history of autoimmune diseases (11). Similarly,
among 45 CRMO patients, 47% of first- or second-de-
gree relatives reportedly had 1 or more chronic inflamma-
tory disorder(s), including psoriasis, IBD, arthritis, and
severe acne (93). Several other SAPHO cases with a family
history of psoriasis (almost always without psoriatic ar-
thritis) have been reported (12,17,24,47,69,94,95),
whereas a family history of ankylosing spondylitis seems
to be rare (47).
Although the familial clustering of SAPHO cases ap-
pears to be more limited than seen in the spondyloar-
thropathies, particularly psoriatic arthritis, it nonetheless
suggests a genetic component in the pathogenesis of the
syndrome. Some of the early studies indicated that the
frequency of HLA-B27 was increased in patients with
SAPHO syndrome compared to the general population
(1,13), although possession of this antigen was nowhere
near as frequent as seen in ankylosing spondylitis (where
85% are positive). Recent studies have reported fre-
quencies between 4% in Italy and 18% in France (17)
(Table 1). Whether this constitutes an excess is difficult to
determine because no phenotype frequencies for the gen-
eral population are provided in these studies. Generally,
between 2% and 9% of most populations of European
descent are HLA-B27 carriers, but the frequency can
range from 0 to 20 worldwide. In an analysis of 25
SAPHO and 120 psoriatic arthritis patients, SAPHO
showed no association with HLA-B27, HLA-Cw6, or
HLA-DR antigens, whereas HLA-Cw6 was associated
with psoriasis and psoriatic arthritis and HLA-B27 was
associated with psoriatic spondylitis (96).
Insights into possible genetic associations may also
come from 2 mouse models with nonsynonymous ho-
mozygous mutations in the PSTPIP2 gene, encoding the
proline serine threonine phosphatase interacting protein
2, spontaneously developing features of CRMO. In addi-
tion, the SAPHO syndrome shares some features with
several human genetic auto-inflammatory diseases with
autosomal-recessive inheritance, including the Majeed
syndrome, PAPA (pyogenic arthritis, pyoderma gangre-
nosum, and acne) syndrome, and deficiency of interleu-
kin-1-receptor antagonist (80,93). The Majeed syndrome
consists of CRMO, anemia due to congenital erythropoi-
esis abnormalities, and transient neutrophilic dermatoses.
It is due to a homozygous mutation of the LPIN2 gene(encoding lipin 2) (97). The PAPA syndrome is caused by
mutations in PSTPIP1. However, an analysis of genetic
susceptibility factors in patients with SAPHO syndrome
did not identify an association of SAPHO syndrome with
LPIN2 (19). There also was no association with PSTPIP2
r with NOD2/CARD15, a gene implicated in Crohn’s
isease, which is a complication in up to 10% of patients
ith SAPHO. No mutations in either PSTPIP1 or
STPIP2 were detected in 10 patients with CRMO (11).
eficiency of interleukin-1 receptor antagonist (IL-1Ra)
roduction due to homozygous mutations in the IL1RN
ene results in an autosomal-recessive auto-inflammatory
isease characterized by aseptic multifocal osteomyelitis,
eriostitis, and pustulosis (98). Affected patients can be
escued by administration of anakinra, the recombinant
uman IL-1RA. Whether SAPHO syndrome is associ-
ted with genetic variants of IL-1RA or related genes has
ot been investigated to date. However, when 6 SAPHO
atients whose disease was refractory to a variety of treat-
ent modalities were treated with anakinra, 5 of them
xperienced considerable pain relief and a reduction in
isease activity, but a complete lack of efficacy was ob-
erved in the sixth patient (99). Treatment with anakinra
f a child with CRMO who exhibited significantly ele-
ated levels of plasma IL-1RA (implying activation of the
L-1 pathway) initially resulted in symptom resolution
nd improvement of disease activity, but efficacy was lost
fter a year (61).
The only significant genetic association reported for
he SAPHO syndrome to date is with the T309G allele
nd the GG genotype of the Mdm2-gene, which were not
ssociated with psoriasis and psoriatic arthritis (100). An
ssociation with the p53 single nucleotide polymorphism
72C just failed to reach statistical significance in that
tudy. The tumor suppressor protein p53 plays an impor-
ant role in cell cycle regulation and apoptosis of damaged
ells and also regulates the transcription factor NF-B,
which is central to a variety of proinflammatory pathways.
Mdm2, in turn, is the most important negative regulator
of p53. Both of the alleles with increased frequencies in
patients with SAPHO syndrome have been associated
with ineffective p53 responses, but it remains to be eluci-
dated which p53 functions are involved in the develop-
ment of this syndrome. Intense expression of TNF
mRNA and protein has been reported in bone biopsy
specimens of a few patients with SAPHO syndrome (52).
In addition, activation of the IL-1 pathway as evidenced
by elevated levels of plasma IL-1RA was reported in an-
other patient (61). The clinical response of SAPHO pa-
tients to treatment with TNF or IL-1 blockade (anakinra)
further suggests that these inflammatory cytokines play an
important role in the pathogenesis of the SAPHO syn-
drome. Therefore, the inhibitory effects of p53/Mdm2
axis on NF-B-induced proinflammatory pathways may
be particularly relevant.
SAPHO syndrome shares a variety of features with the
seronegative spondyloarthropathies (SpAs), including
M.T. Nguyen et al. 263sacroiliitis, enthesitis, paravertebral ossifications, and an-
kylosis. The association with IBD and psoriasis is another
characteristic common to both SAPHO syndrome and
SpAs. In addition, pustular psoriasis and PPP are difficult
to distinguish histologically and clinically and may repre-
sent the same entity. On the other hand, carriage of HLA-
B27 is classically linked with the SpAs, particularly with
ankylosing spondylitis, where the prevalence of this anti-
gen exceeds 85% (101,102). Nevertheless, HLA-B27 is at
best only moderately overrepresented in patients with SA-
PHO syndrome. A better comprehension of the nosologic
relation between SAPHO syndrome and the seronegative
SpAs may eventually provide insights into the pathogen-
esis of SAPHO syndrome. Currently, however, such an
understanding not only remains elusive but also would
not be very useful because the pathogenetic mechanisms
of the SpAs also remain largely unknown. A variety of
mechanisms have been proposed for ankylosing spondy-
litis, but essentially all of them involve HLA-B27 (103).
Reactive arthritis is caused by infectious organisms, the
presence of which would exclude a diagnosis of SAPHO
syndrome. It, too, is strongly associated with HLA-B27.
SAPHO syndrome encompasses a broad spectrum of
hyperostotic and osteitic lesions associated with dermato-
logic manifestations. It is believed to share some charac-
teristics with spondyloarthropathies and other autoim-
mune diseases (104), but more likely is in the auto-
inflammatory part of the spectrum of immunologic
diseases (105). Recognition of SAPHO syndrome is im-
portant to avoid unnecessary invasive procedures and pro-
longed antibiotic treatment of osteoarticular lesions.
However, the course of the disease is benign and the long-
term functional prognosis is good if promptly diagnosed
and treated (106).
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